An editorial in the New England Journal of Medicine (NEJM) issue of 23 September 2010 took the unusual position of challenging a study published in the same issue.
Cost of new drug challenged
Home/Pharma News | Posted 21/01/2011 0 Post your comment
The challenge from Dr Lee Goldman and Dr Jeffrey Ginsberg in their editorial focussed around the cost of the treatment compared to the relative benefit, a growing debate in American medicine.
The study published in the NEJM proved that a blood-thinning medicine could prevent problems from worsening in some people with a sometimes painful, usually short-term and non-fatal, blood clot near the surface of the leg, called superficial-vein thrombosis.
The editorial, however, challenged the costs of the treatment (ranging from US$2,124–7,380 per patient to receive injections for 45 days) to prevent one out of 88 patients from having a more dangerous, but rarely fatal, deep vein clot.
The issue of cost-effectiveness is becoming a hot topic as more Americans become eligible for Medicare insurance, drug rebates increase and new healthcare reform aims to bring affordable health care to 30 million more people by 2019.
Healthcare expenditure in the US is already higher than any other country, and currently spends about 18% of the gross domestic product on health care.
Related article
Source: NEJM, New York Times.
Guidelines
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Comments (0)
Post your comment